Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Angela Cramer"'
Autor:
Simon Timbrell, Hosam Aglan, Angela Cramer, Phil Foden, David Weaver, Jonathan Pachter, Aoife Kilgallon, Robert B. Clarke, Gillian Farnie, Nigel J. Bundred
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Abstract Cancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant
Externí odkaz:
https://doaj.org/article/0042b7fcefc749e8a9c051f9adcd6bb2
Autor:
Angela Lamarca, Salvatore Galdy, Jorge Barriuso, Sharzad Moghadam, Elizabeth Beckett, Jane Rogan, Alison Backen, Catherine Billington, Mairéad G McNamara, Richard A Hubner, Angela Cramer, Juan W Valle
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0206007 (2018)
INTRODUCTION:Expression of human epidermal growth factor receptor (HER)2 and HER3 have been investigated in small BTC studies using variable scoring systems. METHODS:HER2 and HER3 overexpression/amplification were explored following internationally a
Externí odkaz:
https://doaj.org/article/63bba2cc6e3d473387d7aa195af23fce
Autor:
Judith M. Bliss, David A. Cameron, Anthony I. Skene, Jane Ooi, Sankaran Narayanan, Jay Naik, James P. Morden, Stuart A. McIntosh, Sarah E. Miller, Kieran Horgan, Sue M. Hartup, Abigail Evans, Marie A. Emson, David Dodwell, Ramsey I. Cutress, Anne Armstrong, Emad A. Rakha, Abeer M. Shaaban, Andrew Hanby, Angela Cramer, Adrian Murray Brunt, Nuria Porta, Nigel Bundred
Supplementary Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2582b40e3e9fb5fd63904f027e23fca8
https://doi.org/10.1158/1078-0432.22487985
https://doi.org/10.1158/1078-0432.22487985
Autor:
Judith M. Bliss, David A. Cameron, Anthony I. Skene, Jane Ooi, Sankaran Narayanan, Jay Naik, James P. Morden, Stuart A. McIntosh, Sarah E. Miller, Kieran Horgan, Sue M. Hartup, Abigail Evans, Marie A. Emson, David Dodwell, Ramsey I. Cutress, Anne Armstrong, Emad A. Rakha, Abeer M. Shaaban, Andrew Hanby, Angela Cramer, Adrian Murray Brunt, Nuria Porta, Nigel Bundred
Supplementary Figure from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bc8932db29ed31281a0cffa784eab54
https://doi.org/10.1158/1078-0432.22487964
https://doi.org/10.1158/1078-0432.22487964
Autor:
Judith M. Bliss, David A. Cameron, Anthony I. Skene, Jane Ooi, Sankaran Narayanan, Jay Naik, James P. Morden, Stuart A. McIntosh, Sarah E. Miller, Kieran Horgan, Sue M. Hartup, Abigail Evans, Marie A. Emson, David Dodwell, Ramsey I. Cutress, Anne Armstrong, Emad A. Rakha, Abeer M. Shaaban, Andrew Hanby, Angela Cramer, Adrian Murray Brunt, Nuria Porta, Nigel Bundred
Purpose:EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer.Patients and Methods:This randomized phase II, two-part, multicenter trial included newly dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735de3c465e80978154bc41d4f2e3c63
https://doi.org/10.1158/1078-0432.c.6532623.v1
https://doi.org/10.1158/1078-0432.c.6532623.v1
Autor:
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, Angela Cramer, Andrew Hanby, Abeer Shaaban, Emad Rakha, Anne Armstrong, Ramsey Cutress, David Dodwell, Marie Emson, Abigail Evans, Sue Hartup, Kieran Horgan, Stuart McIntosh, Jay Naik, Samkaran Narayanan, Jane Oii, Anthony Skene, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:P2-13
Background: EPHOS-B is a multi-centre randomized trial designed to investigate whether anti-HER2 therapy given 11 days pre-surgery inhibited proliferation and/or increased apoptosis in HER2-positive early breast cancer. Significant differences in Ki6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e00e6d4ba5bcb356c2aff20c4664e2f5
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-08
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-08
Autor:
Catherine Billington, Alison Backen, Sharzad Moghadam, Jane Rogan, Richard A Hubner, Juan W. Valle, Salvatore Galdy, Mairéad G McNamara, Elizabeth A. H. Beckett, Angela Lamarca, Jorge Barriuso, Angela Cramer
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0206007 (2018)
Lamarca, A, Galdy, S, Barriuso, J, Moghadam, S, Beckett, E, Rogan, J, Backen, A, Billington, C, Mcnamara, M, Hubner, R, Cramer, A & Valle, J 2018, ' The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers ', P L o S One, vol. 13, no. 10, e0206007 . https://doi.org/10.1371/journal.pone.0206007
PLoS ONE, Vol 13, Iss 10, p e0206007 (2018)
Lamarca, A, Galdy, S, Barriuso, J, Moghadam, S, Beckett, E, Rogan, J, Backen, A, Billington, C, Mcnamara, M, Hubner, R, Cramer, A & Valle, J 2018, ' The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers ', P L o S One, vol. 13, no. 10, e0206007 . https://doi.org/10.1371/journal.pone.0206007
IntroductionExpression of human epidermal growth factor receptor (HER)2 and HER3 have been investigated in small BTC studies using variable scoring systems. Methods HER2 and HER3 overexpression/amplification were explored following internationally ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f476ed27f49cbd140ef458625016916
http://europepmc.org/articles/PMC6193702
http://europepmc.org/articles/PMC6193702
Autor:
Angela Lamarca, Juan W. Valle, Sharzad Moghadam, Salvatore Galdy, Angela Cramer, Jane Rogan, Mairéad G McNamara, Richard A Hubner
Publikováno v:
Lamarca, A, Galdy, S, Moghadam, S, Rogan, J, Mcnamara, M, Hubner, R, Cramer, A & Valle, J 2017, ' HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs) : A retrospective analysis ', ESMO 2017 Congress, Madrid, Spain, 8/09/17-12/09/17 . < https://doi.org/10.1093/annonc/mdx369.108 >
Background: Cholangiocarcinoma (CC), gallbladder cancer (GBC) and ampullary cancer (AC) (collectively BTCs) are poor-prognosis cancers. Cisplatin-gemcitabine chemotherapy is the standard treatment for patients (pts) with advanced BTC. New treatment t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771323a176b3201c1097f69437a634b1
https://doi.org/10.1093/annonc/mdx369.108
https://doi.org/10.1093/annonc/mdx369.108
Publikováno v:
Cancer Research. 70:P3-10
Background: UK screen detected breast cancers (SDBC) (aged 50-65 years) have an overall 97.2% 5 year relative survival compared to 77.6% for symptomatic cancers. Epithelial proliferation has been used to determine therapy in the St. Gallen guidelines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f7b69ff92488ad4c3b4392cf0d27643
https://doi.org/10.1158/0008-5472.sabcs10-p3-10-31
https://doi.org/10.1158/0008-5472.sabcs10-p3-10-31
Autor:
R Morley, Angela Cramer, S Narayanan, Nigel J Bundred, J Naik, Andrew Evans, Murray Brunt, Judith M Bliss, Abeer M Shaaban, A Hong, J Ooi, David Cameron, E. Kalaitzaki, Andrew M. Hanby, Kieran Horgan, Mark Webster-Smith
Publikováno v:
Cancer Research. 76:PD5-06
Background: Patients diagnosed with primary breast cancer (BC) often have a couple weeks interval between diagnosis and definitive surgery. This time window provides the opportunity for assessing biological drug effects in a treatment naive populatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37c20436bd4b5bb11cbf3c31e415037a
https://doi.org/10.1158/1538-7445.sabcs15-pd5-06
https://doi.org/10.1158/1538-7445.sabcs15-pd5-06